Cover Image
Market Research Report

Europe Anti-Nuclear Antibody Test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Published by Data Bridge Market Research Private Limited Product code 610296
Published Content info 248 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Anti-Nuclear Antibody Test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
Published: February 18, 2018 Content info: 248 Pages
Description

The Europe anti-nuclear antibody test market is expected to reach USD 491.05 million by 2025, from USD 268.98 million in 2017 growing at a CAGR of 7.9% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

The key market players for Europe anti-nuclear antibody test market are listed below:

  • Bio-Rad Laboratories, Inc.
  • Alere, Inc.
  • Trinity Biotech
  • Thermo Fisher Scientific Inc.
  • Antibodies Inc.
  • EUROIMMUN AG
  • Immuno Concepts

The market is further segmented into:

  • Product
  • Test
  • Disease
  • End-user

The Europe anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the Europe anti-nuclear antibody test market with 59.2% market share and is expected to reach USD 294.67 million by 2025, with the highest CAGR of 8.1% in the forecast period 2018 to 2025.

The Europe anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, indirect immunofluorescence is expected to dominate the Europe anti-nuclear antibody test market with 59.9% market share and is expected to reach USD 284.10 million by 2025, with the CAGR of 7.4% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 9.2% in the forecast period, and is expected to reach USD 82.42 million in 2025 from USD 41.21 million in 2017.

The Europe anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, systemic lupus erythematosus is expected to dominate the Europe anti-nuclear antibody test market with 51.3% market share and is expected to reach USD 256.05 million by 2025, with the highest CAGR of 8.2% in the forecast period 2018 to 2025.

The Europe anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the Europe anti-nuclear antibody test market with 60.3% market share and is expected to reach USD 299.43 million by 2025, with the highest CAGR of 8.1% in the forecast period 2018 to 2025.

Based on geography, the Europe anti-nuclear antibody test market is segmented into geographical regions, such as,

  • Germany,
  • United Kingdom,
  • France,
  • Spain,
  • Italy,
  • Russia,
  • Turkey,
  • Belgium,
  • Nether lands,
  • Switzerland,
  • Rest of Europe

Covered in this report:

The report covers the present scenario and the growth prospects of the Europe anti-nuclear antibody test for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. OVERVIEW OF EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET
  • 1.4. CURRENCY AND PRICING
  • 1.5. LIMITATION
  • 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

  • 2.1. MARKETS COVERED
  • 2.2. GEOGRAPHIC SCOPE
  • 2.3. YEARS CONSIDERED FOR THE STUDY
  • 2.4. CURRENCY AND PRICING
  • 2.5. RESEARCH METHODOLOGY
  • 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7. SECONDARY SOURCES
  • 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

  • 3.1. DRIVERS
    • 3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
    • 3.1.2. RISING MEDICAL INSURANCE
    • 3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION
  • 3.2. RESTRAINTS
    • 3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL
  • 3.3. OPPORTUNITIES
    • 3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
    • 3.3.2. EMERGING MARKETS
    • 3.3.3. LABORATORY AUTOMATION FAVORS THE MARKET
  • 3.4. CHALLENGES
    • 3.4.1. LACK OF SKILLED PROFESSIONALS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

  • 6.1. OVERVIEW
  • 6.2. ASSAY KITS & REAGENTS
  • 6.3. SYSTEMS
  • 6.4. SOFTWARE

7. EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST

  • 7.1. OVERVIEW
  • 7.2. INDIRECT IMMUNOFLUORESCENCE
  • 7.3. ELISA
  • 7.4. MULTIPLEX TESTING

8. EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE

  • 8.1. OVERVIEW
  • 8.2. RHEUMATOID ARTHRITIS
  • 8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
  • 8.4. SJOGREN'S SYNDROME
  • 8.5. SCLERODERMA
  • 8.6. POLYMYOSITIS
  • 8.7. OTHERS

9. EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER

  • 9.1. OVERVIEW
  • 9.2. HOSPITALS
  • 9.3. CLINICS
  • 9.4. PHYSICIAN OFFICE LABORATORIES
  • 9.5. OTHERS

10. EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY

  • 10.1. OVERVIEW
  • 10.2. EUROPE
    • 10.2.1. GERMANY
    • 10.2.2. FRANCE
    • 10.2.3. U.K.
    • 10.2.4. ITALY
    • 10.2.5. SPAIN
    • 10.2.6. SWITZERLAND
    • 10.2.7. NETHERLANDS
    • 10.2.8. BELGIUM
    • 10.2.9. RUSSIA
    • 10.2.10. TURKEY
    • 10.2.11. REST OF EUROPE

11. EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET,

COMPANY LANDSCAPE 220

  • 11.1. COMPANY SHARE ANALYSIS: EUROPE
  • 11.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 11.3. COMPANY SHARE ANALYSIS: EUROPE
  • 11.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

12. COMPANY PROFILES

  • 12.1. THERMO FISHER SCIENTIFIC INC.
    • 12.1.1. COMPANY OVERVIEW
    • 12.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS
    • 12.1.3. PRODUCT PORTFOLIO
    • 12.1.4. RECENT DEVELOPMENTS
  • 12.2. MERCK KGAA
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. MERCK KGAA: REVENUE ANALYSIS
    • 12.2.3. PRODUCT PORTFOLIO
    • 12.2.4. RECENT DEVELOPMENTS
  • 12.3. ALERE INC.
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. ALERE INC.: REVENUE ANALYSIS
    • 12.3.3. PRODUCT PORTFOLIO
    • 12.3.4. RECENT DEVELOPMENTS
  • 12.4. TRINITY BIOTECH
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. TRINITY BIOTECH: COMPANY OVERVIEW
    • 12.4.3. PRODUCT PORTFOLIO
    • 12.4.4. RECENT DEVELOPMENTS
  • 12.5. ANTIBODIES INC.
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. ANTIBODIES INC.: REVENUE ANALYSIS
    • 12.5.3. PRODUCT PORTFOLIO
    • 12.5.4. RECENT DEVELOPMENTS
  • 12.6. BIO-RAD LABORATORIES, INC.
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
    • 12.6.3. PRODUCT PORTFOLIO
    • 12.6.4. RECENT DEVELOPMENTS
  • 12.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. PERKINELMER INC.: REVENUE ANALYSIS
    • 12.7.3. PRODUCT PORTFOLIO
    • 12.7.4. RECENT DEVELOPMENTS
  • 12.8. IMMUNO CONCEPTS
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. IMMUNO CONCEPTS: COMPANY SNAPSHOT
    • 12.8.3. PRODUCT PORTFOLIO
    • 12.8.4. RECENT DEVELOPMENTS
  • 12.9. INOVA DIAGNOSTICS
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. INOVA DIAGNOSTICS:COMPANY SNAPSHOT
    • 12.9.3. PRODUCT PORTFOLIO
    • 12.9.4. RECENT DEVELOPMENTS
  • 12.10. ZEUS SCIENTIFIC, INC.
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
    • 12.10.3. PRODUCT PORTFOLIO
    • 12.10.4. RECENT DEVELOPMENTS
  • 12.11. MBL INTERNATIONAL
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. MBL INTERNATIONAL: COMPANY SNAPSHOT
    • 12.11.3. PRODUCT PORTFOLIO
    • 12.11.4. RECENT DEVELOPMENTS
  • 12.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD
    • 12.12.1. COMPANY OVERVIEW
    • 12.12.2. MEDSOURCE OZONE BIOMEDICALS PVT. LTD: COMPANY SNAPSHOT
    • 12.12.3. PRODUCT PORTFOLIO
    • 12.12.4. RECENT DEVELOPMENTS

  • 12.13. AESKU GROUP GMBH & CO. KG
    • 12.13.1. COMPANY OVERVIEW
    • 12.13.2. AESKU GROUP GMBH & CO. KG: COMPANY SNAPSHOT
    • 12.13.3. PRODUCT PORTFOLIO
    • 12.13.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

LIST OF TABLES

TABLE LIST

TABLE 1 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 57

TABLE 2 EUROPE ASSAY KITS & REAGENTS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 58

TABLE 3 EUROPE SYSTEMS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 59

TABLE 4 EUROPE SOFTWARES MARKET, BY REGION, 2016 - 2025 (USD MILLION) 60

TABLE 5 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST,

2016 - 2025 (USD MILLION) 63

TABLE 6 EUROPE INDIRECT IMMUNOFLUORESCENCE MARKET, BY REGION,

2016 - 2025 (USD MILLION) 64

TABLE 7 EUROPE ELISA MARKET, BY REGION, 2016 - 2025 (USD MILLION) 65

TABLE 8 EUROPE MULTIPLEX TESTING MARKET, BY REGION,

2016 - 2025 (USD MILLION) 66

TABLE 9 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 69

TABLE 10 EUROPE RHEUMATOID ARTHRITIS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 70

TABLE 11 EUROPE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 71

TABLE 12 EUROPE SJOGREN'S SYNDROME MARKET, BY REGION,

2016 - 2025 (USD MILLION) 72

TABLE 13 EUROPE SCLERODERMA MARKET, BY REGION,

2016 - 2025 (USD MILLION) 73

TABLE 14 EUROPE POLYMYOSITIS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 74

TABLE 15 EUROPE OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 75

TABLE 16 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 78

TABLE 17 EUROPE HOSPITALS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 79

TABLE 18 EUROPE CLINICS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 80

TABLE 19 EUROPE PHYSICIAN OFFICE LABORATORIES MARKET, BY REGION,

2016 - 2025 (USD MILLION) 81

TABLE 20 EUROPE OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 82

TABLE 21 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY REGION,

2016 - 2025 (USD MILLION) 90

TABLE 22 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY,

2016-2025 (USD MILLION) 116

TABLE 23 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 117

TABLE 24 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 117

TABLE 25 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 118

TABLE 26 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 119

TABLE 27 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 120

TABLE 28 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 120

TABLE 29 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 121

TABLE 30 GERMANY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 122

TABLE 31 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 123

TABLE 32 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 123

TABLE 33 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 124

TABLE 34 FRANCE ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 125

TABLE 35 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 126

TABLE 36 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 126

TABLE 37 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 127

TABLE 38 U.K. ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 128

TABLE 39 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 129

TABLE 40 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 129

TABLE 41 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 130

TABLE 42 ITALY ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 131

TABLE 43 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 132

TABLE 44 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 132

TABLE 45 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 133

TABLE 46 SPAIN ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 134

TABLE 47 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 135

TABLE 48 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY TEST,

2016 - 2025 (USD MILLION) 135

TABLE 49 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 136

TABLE 50 SWITZERLAND ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 137

TABLE 51 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 138

TABLE 52 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 138

TABLE 53 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 139

TABLE 54 NETHERLANDS ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 140

TABLE 55 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 141

TABLE 56 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 141

TABLE 57 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 142

TABLE 58 BELGIUM ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 143

TABLE 59 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 144

TABLE 60 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 144

TABLE 61 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 145

TABLE 62 RUSSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 146

TABLE 63 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 147

TABLE 64 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 147

TABLE 65 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 148

TABLE 66 TURKEY ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 149

TABLE 67 REST OF EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 150

LIST OF FIGURES

FIGURES LIST

FIGURE 1 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: SEGMENTATION 27

FIGURE 2 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: DATA TRIANGULATION 30

FIGURE 3 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET : RESEARCH SNAPSHOT 31

FIGURE 4 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET : BOTTOM UP APPROACH 32

FIGURE 5 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: TOP DOWN APPROACH 32

FIGURE 6 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET :

INTERVIEW DEMOGRAPHICS 33

FIGURE 7 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET : SEGMENTATION 46

FIGURE 8 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY PRODUCT TYPE, 2017 56

FIGURE 9 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY TEST, 2017 62

FIGURE 10 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY DISEASE, 2017 68

FIGURE 11 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY END USER, 2017 77

FIGURE 12 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET SNAPSHOT (2017) 85

FIGURE 13 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2017) 86

FIGURE 14 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2018) 87

FIGURE 15 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017 & 2025) 88

FIGURE 16 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY PRODUCT TYPE (2018 & 2025) 89

FIGURE 17 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) 111

FIGURE 18 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) 112

FIGURE 19 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 113

FIGURE 20 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY COUNTRY (2017 & 2025) 114

FIGURE 21 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT (2018 & 2025) 115

FIGURE 22 EUROPE ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) 222

Back to Top